Bayer wins US nod for Jivi
admin 31st August 2018 Uncategorised 0US regulators have approved Bayer’s Jivi (formerly BAY94-9027), a longer-acting Factor VIII therapy designed to reduce the number of infusions necessary to prevent bleeds in patients with Haemophilia A.
More: Bayer wins US nod for Jivi
Source: News